Chandler Robinson

Insider Reports History

Location
Wilmette, IL
Signature
/s/ Quan Vu, Attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Chandler Robinson:

Company Role Class Num Shares Value Price $ Report Date Ownership
Monopar Therapeutics Chief Executive Officer, Director Common Stock 85,718 $5,596,768 $65.29 28 Jan 2025 Direct
Monopar Therapeutics Chief Executive Officer, Director Common Stock 62,815 $4,101,367 $65.29 28 Jan 2025 Indirect
Monopar Therapeutics Chief Executive Officer, Director Restricted Stock Units 121,732 $3,446,898 $36.41 02 Dec 2025 Direct
Monopar Therapeutics Chief Executive Officer, Director Restricted Stock Unit 113,008 31 Dec 2025 Direct
Monopar Therapeutics Chief Executive Officer, Director Stock Options 16,753 02 Dec 2025 Direct

Insider Reports Filed by Chandler Robinson

Symbol Company Period Transactions Value $ Form Type Role Filing Time
MNPR Monopar Therapeutics 31 Dec 2025 3 -$167,037 4 Chief Executive Officer, Director 05 Jan 2026, 15:46
MNPR Monopar Therapeutics 02 Dec 2025 2 $0 4 Chief Executive Officer, Director 08 Dec 2025, 16:46
MNPR Monopar Therapeutics 30 Sep 2025 3 -$216,099 4 Chief Executive Officer, Director 02 Oct 2025, 15:04
MNPR Monopar Therapeutics 14 Jul 2025 3 -$671,936 4 Chief Executive Officer, Director 16 Jul 2025, 21:02
MNPR Monopar Therapeutics 30 Jun 2025 3 -$209,850 4 Chief Executive Officer, Director 02 Jul 2025, 16:25
MNPR Monopar Therapeutics 31 Mar 2025 3 -$43,838 4 Chief Executive Officer, Director 02 Apr 2025, 21:07
MNPR Monopar Therapeutics 04 Mar 2025 5 -$55,760 4 Chief Executive Officer, Director 07 Mar 2025, 21:24
MNPR Monopar Therapeutics 28 Jan 2025 1 $0 4 Chief Executive Officer, Director 30 Jan 2026, 14:31
MNPR Monopar Therapeutics 31 Dec 2024 3 -$48,598 4 Chief Executive Officer, Director 02 Jan 2025, 18:14
MNPR Monopar Therapeutics 30 Sep 2024 3 -$12,927 4 Chief Executive Officer, Director 02 Oct 2024, 19:45
MNPR Monopar Therapeutics 30 Jun 2024 3 -$6,348 4 Chief Executive Officer, Director 02 Jul 2024, 18:07
MNPR Monopar Therapeutics 28 May 2024 2 +$84 4 Chief Executive Officer, Director 30 May 2024, 18:10
MNPR Monopar Therapeutics 31 Mar 2024 3 -$4,884 4 Chief Executive Officer, Director 02 Apr 2024, 20:33
MNPR Monopar Therapeutics 31 Dec 2023 6 -$3,673 4 Chief Executive Officer, Director 03 Jan 2024, 19:36
MNPR Monopar Therapeutics 30 Sep 2023 3 -$4,446 4 Chief Executive Officer, Director 03 Oct 2023, 19:37
MNPR Monopar Therapeutics 30 Jun 2023 3 -$8,780 4 Chief Executive Officer, Director 03 Jul 2023, 18:45
MNPR Monopar Therapeutics 31 Mar 2023 3 -$5,958 4 Chief Executive Officer, Director 04 Apr 2023, 17:17
MNPR Monopar Therapeutics 01 Feb 2023 2 $0 4 Chief Executive Officer, Director 03 Feb 2023, 17:49
MNPR Monopar Therapeutics 31 Dec 2022 6 -$16,924 4 Chief Executive Officer, Director 03 Jan 2023, 14:59
MNPR Monopar Therapeutics 30 Sep 2022 3 -$6,197 4 Chief Executive Officer, Director 03 Oct 2022, 19:55
MNPR Monopar Therapeutics 30 Jun 2022 3 -$16,091 4 Chief Executive Officer, Director 01 Jul 2022, 16:07
MNPR Monopar Therapeutics 31 Mar 2022 3 -$2,945 4 Chief Executive Officer, Director 01 Apr 2022, 17:28
MNPR Monopar Therapeutics 02 Feb 2022 2 $0 4 Chief Executive Officer, Director 04 Feb 2022, 18:37
MNPR Monopar Therapeutics 01 Jan 2022 3 -$7,470 4 Chief Executive Officer, Director 04 Jan 2022, 13:17
MNPR Monopar Therapeutics 31 Dec 2021 3 -$4,378 4 Chief Executive Officer, Director 04 Jan 2022, 13:07
MNPR Monopar Therapeutics 30 Sep 2021 3 -$5,625 4 Chief Executive Officer, Director 01 Oct 2021, 19:24
MNPR Monopar Therapeutics 30 Jun 2021 3 -$13,606 4 Chief Executive Officer, Director 02 Jul 2021, 17:10